A Phase 1/2 interventional study of ALE.P02 and Pembrolizumab in Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Cervical Squamous Cell Carcinoma, sponsored by Alentis Therapeutics AG. Recruiting at 41 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Alentis Therapeutics AG · Phase 1/2, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.
Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 61st largest by planned enrollment of the 161 interventional ones that give a count, is one of 15 that started in 2024, is one of 33 in phase 1/2, reaches primary completion later than 41 of the 69 other live ones, and was the 152nd registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Spain, United States, Austria and 11 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Spain, United States, Australia and 3 more countries
Ages 18+
IDEAYA Biosciences · Sites in Spain, United States, Georgia
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Spain, United States, Canada and 1 more country
Ages 18+
Johnson & Johnson Enterprise Innovation Inc. · Sites in Spain, United States, France and 1 more country
Ages 18–74
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 79 · Phase 3 35
First in 1994; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 235 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 160 across the 161 interventional studies, 1,443 across the 6 observational. Of the 94 that completed or were terminated, 44 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 167 have an industry lead sponsor. The 10 most frequent:
Alentis Therapeutics AG is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Alentis Therapeutics AG has 2 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
19 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05815927Phase 3European Organisation for Research and Treatment of Cancer - EORTCPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer | 2027-07-15 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT05238883HiFiBiO TherapeuticsA Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04180371BicycleTx LimitedStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination with pembrolizumab in adult patients with selected squamous solid tumors.
This Study has a Phase I ALE.P02 monotherapy dose escalation and recommended dose for expansion (RDE) study of ALE.P02 as a monotherapy and combination therapy with pembrolizumab, and a Phase II study of ALE.P02 as a monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive ALE.P02 as monotherapy via intravenous infusion. The ALE.P02 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Phase I dose escalation part of the study.
Drug: ALE.P02
Patients will receive ALE.P02 as monotherapy via intravenous infusion. The safe recommended dose of ALE.P02 will be given in Phase I dose expansion part of the study to identify Recommended Phase II Dose (RP2D).
Drug: ALE.P02
Patients will receive ALE.P02 as monotherapy via intravenous infusion at the RP2D, or according to the dosing schedule after the dose expansion phase.
Drug: ALE.P02
Patients will receive ALE.P02 in combination with pembrolizumab via intravenous infusion. The ALE.P02 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined.
Drug: ALE.P02 · Drug: Pembrolizumab
Patients will receive ALE.P02 in combination with pembrolizumab via intravenous infusion. The safe recommended dose of ALE.P02 will be given in Phase I dose expansion part of the study.
Drug: ALE.P02 · Drug: Pembrolizumab
ALE.P02 will be administered by IV infusion according to the assigned arms.
Pembrolizumab will be administered per local labeling or institutional guidelines.
Number of Patients with Dose Limiting Toxicities (DLTs)
DLTs as defined in the protocol will be assessed to evaluate safety and tolerability of ALE.P02 as a monotherapy or in combination with pembrolizumab (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE).
Time frame: Up to 28 days
Number of Patients with Adverse Events
Adverse events will be assessed to evaluate safety and tolerability of ALE.P02 as a monotherapy or in combination with pembrolizumab (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE).
Time frame: Screening (day -28 to day -1) up to Safety follow-up (30 ± 5 days post last dose [Up to 3.5 years])
Overall Response Rate (ORR) (Phase I)
The ORR is the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) This is assessed to establish RP2D for ALE.P02 (Phase I RDE)
Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)
Duration of Response (DoR) (Phase I)
The DoR is defined for patients achieving a confirmed CR or PR as the time from the initial response of CR or PR per Investigator review according to RECIST 1.1 to disease progression or death of any cause, whichever occurs earlier. This is assessed to establish RP2D for ALE.P02 (Phase I RDE).
Time frame: From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years)
Overall Response Rate (ORR) (Phase II)
The ORR is assessed to assess evaluate anti-tumor activity of ALE.P02 as a monotherapy (Phase II).
Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)
Duration of Response (DoR) (Phase II)
The DoR is assessed to evaluate assess anti-tumor activity of ALE.P02 as a monotherapy (Phase II).
Time frame: From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years)
Disease control rate (DCR) (Phase I and II)
The DCR is defined as the proportion of patients with a confirmed BOR of CR or PR or stable disease (SD) per Investigator review according to RECIST 1.1 at or prior to initiation of the use of new anti-cancer therapy. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).
Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)
Median Progression-Free Survival (PFS) at 6 and 12 Months (Phase I and II)
The PFS is defined as time from first study treatment to a documented disease progression according to RECIST 1.1, as determined by the Investigator, or death due to any cause, whichever occurs earlier. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).
Time frame: At 6 and 12 months after initiation of ALE.P02 treatment
Median Overall Survival (OS) at 6, 12, and 24 Months (Phase I and II)
The OS is defined as time from first study treatment to death due to any cause. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).
Time frame: At 6, 12, and 24 months after initiation of ALE.P02 treatment
Blood Concentration of ALE.P02 Antibody-drug Conjugate (ADC)
Concentrations of ALE.P02 ADC in blood will be measured at each scheduled time point per arms to assess the pharmacokinetic (PK) profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at end of treatment visit (EoT) (Up to 3.5 years)
Blood Concentration of Total Antibody
Total antibody in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Blood Concentrations of Payload
Concentrations of payload in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Area under the concentration-time curve over the dosing interval (AUCtau)
The AUCtau of ALE.P02 will be measured to assess the pharmacokinetic (PK) profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)
The AUClast of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)
The AUCinf of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Maximum Concentration (Cmax)
The Cmax of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Minimum concentration (Cmin)
The Cmin of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Concentration at the end of a Dosing Interval (Ctrough)
The Ctrough of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
The terminal elimination rate constant (KeL)
The KeL of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined by selection of at least three data points on the terminal phase of the concentration-time curve.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Terminal elimination half-life (t½)
The t½ of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Time of Maximum Concentration (tmax)
The tmax of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Average Concentration (Cavg)
The Cavg of ALE.P02 will be measured to assess the PK profile of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Number of Patients with Presence of anti-ALE.P02 Antibodies
Presence of anti-ALE.P02 Antibodies will be assessed to evaluate the immunogenicity of ALE.P02.
Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Dec 2024 (actual). Primary completion is estimated for Feb 2028, 37 months after the start.
Of 92 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 37 months is below that.
Counting every sponsor, half of 137 studies reached it within 61 months; a quarter within 47 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
Alentis Therapeutics AG